170 related articles for article (PubMed ID: 38340948)
1. Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms.
Collins TB; Laranjeira ABA; Kong T; Fulbright MC; Fisher DAC; Sturgeon CM; Batista LFZ; Oh ST
Exp Hematol; 2024 Apr; 132():104178. PubMed ID: 38340948
[TBL] [Abstract][Full Text] [Related]
2. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
3. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
4. Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2
Yuan J; Song J; Chen C; Lv X; Bai J; Yang J; Zhou Y
Invest New Drugs; 2022 Dec; 40(6):1194-1205. PubMed ID: 36044173
[TBL] [Abstract][Full Text] [Related]
5. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Martínez-Avilés L; Besses C; Álvarez-Larrán A; Torres E; Serrano S; Bellosillo B
Ann Hematol; 2012 Apr; 91(4):533-41. PubMed ID: 21904853
[TBL] [Abstract][Full Text] [Related]
6.
Shi Z; Liu J; Zhao Y; Yang L; Cai Y; Zhang P; Xu Z; Qin T; Qu S; Pan L; Wu J; Yan X; Li Z; Zhang W; Yan Y; Huang H; Huang G; Li B; Wu X; Xiao Z
Haematologica; 2023 May; 108(5):1359-1373. PubMed ID: 36005555
[TBL] [Abstract][Full Text] [Related]
7. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Benson KL; Mesa RA
Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
[TBL] [Abstract][Full Text] [Related]
8. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
9. Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients.
Saliba J; Hamidi S; Lenglet G; Langlois T; Yin J; Cabagnols X; Secardin L; Legrand C; Galy A; Opolon P; Benyahia B; Solary E; Bernard OA; Chen L; Debili N; Raslova H; Norol F; Vainchenker W; Plo I; Di Stefano A
PLoS One; 2013; 8(9):e74257. PubMed ID: 24066127
[TBL] [Abstract][Full Text] [Related]
10. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
11. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
Ramos TL; Sánchez-Abarca LI; Redondo A; Hernández-Hernández Á; Almeida AM; Puig N; Rodríguez C; Ortega R; Preciado S; Rico A; Muntión S; Porras JRG; Del Cañizo C; Sánchez-Guijo F
Oncotarget; 2017 Apr; 8(17):28187-28202. PubMed ID: 28390197
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
13. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
14. The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms.
Byun JM; Song S; Koh Y; Yoon SS; Kim D
Anticancer Res; 2019 Nov; 39(11):6273-6282. PubMed ID: 31704857
[TBL] [Abstract][Full Text] [Related]
15. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
Rampal R; Al-Shahrour F; Abdel-Wahab O; Patel JP; Brunel JP; Mermel CH; Bass AJ; Pretz J; Ahn J; Hricik T; Kilpivaara O; Wadleigh M; Busque L; Gilliland DG; Golub TR; Ebert BL; Levine RL
Blood; 2014 May; 123(22):e123-33. PubMed ID: 24740812
[TBL] [Abstract][Full Text] [Related]
16. Protein arginine methyltransferase 6 controls erythroid gene expression and differentiation of human CD34
Herkt SC; Kuvardina ON; Herglotz J; Schneider L; Meyer A; Pommerenke C; Salinas-Riester G; Seifried E; Bonig H; Lausen J
Haematologica; 2018 Jan; 103(1):18-29. PubMed ID: 29025910
[TBL] [Abstract][Full Text] [Related]
17. Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.
Yao H; Ma Y; Hong Z; Zhao L; Monaghan SA; Hu MC; Huang LJ
Leukemia; 2017 Oct; 31(10):2122-2131. PubMed ID: 28057939
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
[TBL] [Abstract][Full Text] [Related]
19. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.
Zhang SJ; Abdel-Wahab O
Curr Hematol Malig Rep; 2012 Mar; 7(1):34-42. PubMed ID: 22170482
[TBL] [Abstract][Full Text] [Related]
20. Genetics of the myeloproliferative neoplasms.
Abdel-Wahab O
Curr Opin Hematol; 2011 Mar; 18(2):117-23. PubMed ID: 21307773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]